FVB/N-Hyou1^{Tg(Tyr)2422BOve}/Mmjax

Stock number: 017396
Research areas: Developmental Biology Research

Description

These OVE#2422B mice harbor a mutation created by random insertion of the Tyro-sd-IRES-loxP-FUGW lentiviral transgene (LV2187). Using inverse PCR analysis, the transgene integration site was identified in intron 18 of the hypoxia up-regulated 1 gene (Hyou1) on chromosome 9 (specifically at the 3'-44,196,317(-) bp position in antisense orientation). The donating investigator reports the phenotype of homozygous mice as: embryonic day (E)8 lethal.

Detailed description

These OVE#2422B mice harbor a mutation created by random insertion of the Tyro-sd-IRES-loxP-FUGW lentiviral transgene (LV2187). Using inverse PCR analysis, the transgene integration site was identified in intron 18 of the hypoxia up-regulated 1 gene (Hyou1) on chromosome 9 (specifically at the 3'-44,196,317(-) bp position in antisense orientation). The donating investigator reports the phenotype of homozygous mice as: embryonic day (E)8 lethal.

Development

A lentiviral transgenic approach was used to generate these mice. The Tyro-sd-IRES-loxP-FUGW lentiviral transgene (LV2187) was designed with a mouse tyrosinase minigene (Tyro) followed by a splice-donor::IRES::loxP sequence in the FUGW self-inactivating HIV-based lentiviral vector backbone. The Tyro-sd-IRES-loxP replaced the ubiquitin-c promoter, EGFP, and WPRE sequences originally found in the FUGW lentiviral vector. The Tyro minigene is composed of the mouse Tyr enhancer region (620 bp), promoter region (500 bp), and 1.7 kbp cDNA sequence (including the stop codon); all in antisense orientation relative to the FUGW backbone. The Tyro minigene is followed by an artificial splice donor sequence, an internal ribosome entry site (IRES), and a loxP site in this construct. This packaged lentiviral construct was injected subzonally (under the zona pellucida) into 1-8 cell stage FVB/N mouse embryos. Because of the random and multiple lentiviral integration sites of a transgene containing tyrosinase, founder mice (F0) may be identified by mosaic pigmentation. Founder mice from line OVE#2422B were bred with FVB/N mice, and pigmented offspring (F1) were bred to FVB/N mice. The resulting offspring (F2) with identical coat colors (medium brown) were subsequently inbred. Using inverse PCR analysis, the transgene integration site was identified in intron 18 of the hypoxia up-regulated 1 gene (Hyou1) on chromosome 9 (specifically at the 3'-44,196,317(-) bp position in antisense orientation). Transgenic males were sent to The Jackson Laboratory Repository (MMRRC-JAX). Upon arrival, these mice were bred to FVB/NJ inbred mice for at least one generation to establish the live colony.

Allele

Symbol: Hyou1^{Tg(Tyr)2422BOve}
Name: transgene lentiviral insertion 2422B, Paul A Overbeek
MGI accession ID: MGI:5286659
Generation method: Transgenic
Attributes: Reporter
Synonyms: OVE#2422B; OVE2422B
Marker symbol: Hyou1
Marker name: hypoxia up-regulated 1
Marker synonyms: 140 kDa; Cab140; CBP-140; Grp170; GRP-170; HSP12A; IMD59; Orp150; ORP-150
Chromosome: 9
Strain of origin: FVB/N
Expressed genes: Tyr,tyrosinase,mouse, laboratory
Molecular note: The Tyro-IRES-sd-loxP-FUGW lentiviral transgene (LV2187) was designed with a mouse tyrosinase minigene (Tyro) followed by an IRES::3xATG::splice-donor::loxP sequence in the FUGW self-inactivating HIV-based lentiviral vector backbone. The Tyro-IRES-sd-loxP replaced the ubiquitin-c promoter, EGFP, and WPRE sequences originally found in the FUGW lentiviral vector. The Tyro minigene is composed of the mouse Tyr enhancer region (623 bp), promoter region (657 bp), and 1566 bp cDNA sequence (including the stop codon); all in antisense orientation relative to the FUGW backbone. The Tyro minigene is followed by an internal ribosome entry site (IRES) ending with ATGs in all three reading frames (3xATG), an artificial splice donor sequence, and a loxP site in this construct. In line 2422B, the lentiviral transgene inserted into intron 18 (NCBI37/mm9; 3'-44,196,317(-)) in antisense orientation relative to the disrupted gene.